Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Botulinum Toxin Type A as a Migraine Preventive Treatment
The safety and efficacy of botulinum toxin type A (BOTOX; Allergan, Inc) in the prevention of migraine is assessed. Expand
Classification of Daily and Near‐Daily Headaches: Proposed Revisions to the IHS Criteria
Transformation of Episodic Migraine Into Daily Headache: Analysis of Factors
Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Objective.—To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.
Transformed or Evolutive Migraine
Efficacy of Gabapentin in Migraine Prophylaxis
Objective.—To compare gabapentin with placebo for use as a prophylactic agent in patients with migraine (with or without aura).
Drug Induced Refractory Headache ‐ Clinical Features and Management
Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled Trial
The safety and efficacy of botulinum toxin type A (BoNT‐A; BOTOX®, Allergan, Inc.) for the prophylactic treatment of chronic daily headache is evaluated. Expand
Double-blind evaluation of glycerol therapy in acute cerebral infarction.
Patients with cerebral infarction treated with glycerol showed significant improvement in neurological status compared to the patients treated with placebo, and the neurological status was evaluated by use of a neurological scoring system. Expand
A Double‐Blind Comparison of OnabotulinumtoxinA (BOTOX®) and Topiramate (TOPAMAX®) for the Prophylactic Treatment of Chronic Migraine: A Pilot Study
There is a need for effective prophylactic therapy for chronic migraine that has minimal side effects and is safe and effective, and this work contributes towards that goal. Expand